Entries by Thomas Gabrielczyk

Rapid implemenation of off-line serialisation

Serialisation of drugs is confronting pharmaceutical companies all over the world with challenges, especially in relation to data handling and the integration of additional equipment and functions into existing packaging lines. Offline solutions, where secondary packaging is serialized directly by the folding-box manufacturer, combined with sophisticated data flow architectures, are a reliable, flexible, and immediately available alternative to inline serialisation.

BIO-Europe more popular than ever

More than 4,000 participants from all over the globe visited Berlin in early November to take part in this year’s BIO-Europe. The event continues to be on the upswing – like the biotech industry itself.

Spain pushes circular bioeconomy

Conversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently opened second-generation biorefinery Clamber.

Stem cells cure deadly human skin disease

For the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional epidermis on a seven-year-old child suffering from junctional epidermolysis bullosa (JEB).

InflaRx Announces Pricing of Initial Public Offering

German inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in total gross proceeds of approximately US$100m.

The hunt for a cure for Huntington’s

Genetic Diseases:?It’s a disease that often strikes people in the prime of life, slowly destroying control over body, mind and personality. It inevitably kills the patient, but usually only after at least a decade of suffering. The underlying cause of Huntington’s disease – a dominant mutation on Chromosome IV – was discovered almost 25 years ago. Now the first trials to target the condition at its source have begun. Chances of finding a cure have never been more realistic.

European biotech stocks: New wave of optimism

In 2017, the European biotech sector witnessed a volume increase in IPOs and follow-on financings. This says the most recent capital market report of BIOCOM which is published during BIO-Europe on November 6.